Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oculis Holding AG filings document its reporting as a Swiss foreign private issuer and its development-stage biopharmaceutical business in ophthalmology and neuro-ophthalmology. Form 6-K reports furnish IFRS consolidated financial statements, interim financial statements, management discussion and analysis, annual reports, press releases, annual general meeting invitations, proxy materials, and current company updates.
The filing record also covers ordinary-share capital structure, registration statement references on Form F-3 and Form S-8, at-the-market offering arrangements, sales agreements, incorporation by reference, shareholder voting matters, and governance materials. Clinical and regulatory disclosures relate to OCS-01, Privosegtor, Licaminlimab, related development programs, liquidity, operating expenses, and the risks associated with advancing investigational drug candidates.
Oculis Holding AG reported the results of its 2026 Annual General Meeting, where shareholders approved all agenda items and elected Gregory D. Perry to the Board of Directors. The board and executive committee were discharged for 2025 and all incumbent directors were re-elected.
Shareholders acknowledged a standalone statutory loss of CHF 33,670,000 for 2025 and resolved to carry forward an accumulated balance sheet loss of CHF 80,247,000. They approved maximum compensation budgets for non-executive directors and the executive committee, including cash and equity-based awards, and endorsed the 2025 compensation report in an advisory vote.
The meeting approved a capital band of 31,020,888 registered shares, corresponding to a share capital range between CHF 620,417.76 and CHF 930,626.64, and a conditional share capital of 12,677,700 shares for employee and similar plans. Following updated articles, the total number of registered shares increased to 62,041,776, with further board approval to issue 5,750,400 new registered shares into treasury, bringing registered shares up to 67,792,176 and resulting in treasury holdings of 9.15% to support the existing at-the-market offering program and other potential offerings.
Oculis Holding reported an unaudited Q1 2026 net loss of CHF 28.9 million (CHF 0.49 per share), narrowing from CHF 33.2 million a year earlier. Total operating expenses rose to CHF 21.9 million as higher share-based compensation and headcount lifted general and administrative costs, while research and development spending declined slightly as key trials neared completion.
Cash, cash equivalents and short-term financial assets reached CHF 222.0 million as of March 31, 2026, helped by CHF 22.4 million of gross proceeds from an at-the-market share program. Management states this funding supports the business into the second half of 2029. The company’s late-stage pipeline advanced, with Phase 3 DIAMOND trials for OCS‑01 in diabetic macular edema completing last patient visits ahead of a June 2026 topline readout, Licaminlimab’s PREDICT‑1 trial recruiting in dry eye disease, and Privosegtor’s PIONEER‑1 trial in optic neuritis supported by FDA Special Protocol Assessment and PRIME and Breakthrough Therapy designations.
Oculis Holding AG reports that LSP 7 and related parties beneficially own 6,950,294 Ordinary Shares as of March 31, 2026. That stake represents 11.8% of the company based on 59,034,438 Ordinary Shares outstanding. The filing states 1,050,000 shares were purchased by LSP 7 on March 11, 2026, and LSP 7 Management B.V. is the sole director of LSP 7.
Oculis Holding AG is calling shareholders to its 2026 Annual General Meeting on May 13, 2026 in Zug, Switzerland, with an in-person meeting and broadcast.
The agenda covers approval of the 2025 annual and consolidated financial statements, carrying forward a balance sheet loss of CHF 80,247,000, and granting discharge to the board and executive committee. Shareholders will vote on re-electing eight directors, electing a new director, appointing compensation committee members, re-electing PricewaterhouseCoopers as auditor, and electing Blum & Partner AG as independent proxy.
Compensation proposals include up to USD 572,000 fixed and USD 2,150,000 equity-based pay for the board, and up to USD 2,500,000 fixed, USD 1,800,000 variable, and USD 18,000,000 equity-based compensation for the executive committee. The board also seeks to increase the capital band so it can issue up to 31,020,888 additional shares and to expand conditional share capital for employee plans to 12,677,700 shares.
A business update highlights three late-stage programs: OCS-01 eye drops for diabetic macular edema with Phase 3 DIAMOND trial readouts expected in June 2026 and a planned U.S. NDA submission in Q4 2026; Licaminlimab for dry eye disease in the PREDICT-1 registrational trial with topline data expected around late 2026; and Privosegtor, which has Breakthrough Therapy, Orphan Drug and PRIME designations and is entering the PIONEER registrational program for optic neuritis and NAION. Oculis reports oversubscribed equity financings exceeding $200 million in 2025 and is targeting disease areas that together represent estimated market opportunities of over $30 billion.
Oculis Holding AG reporting persons filed an amended Schedule 13G/A stating that Beyeotech directly holds 2,436,902 Ordinary Shares, representing 4.14% of the outstanding ordinary shares based on February 13, 2026 and a reported share count of 58,932,987 Ordinary Shares.
The statement names the related filers—BVCF IV, L.P., Beyeotech, BVCF IV GP, Ltd. and Zhi Yang—and explains their ownership and control relationships, including that GP is the general partner of the Fund and Mr. Zhi Yang is sole shareholder/director of GP.
Oculis Holding AG reported a 2025 net loss of CHF 98.96m, compared with a CHF 85.78m loss in 2024, as it advanced late-stage ophthalmic drug development. Research and development expenses rose to CHF 57.1m, while general and administrative costs reached CHF 25.8m, driven mainly by clinical programs and share-based compensation.
Despite ongoing losses, Oculis strengthened its balance sheet. Cash and cash equivalents were CHF 81.33m and short-term financial assets were CHF 131.68m as of December 31, 2025, following underwritten offerings totaling CHF 178.9m in gross proceeds. Total equity increased to CHF 196.07m and total assets to CHF 235.96m, giving the company resources to fund its pipeline.
Separately, Oculis renewed its at-the-market equity program by entering into an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 shelf registration. The ATM program permits offers and sales, at the company’s discretion, of ordinary shares up to an aggregate offering price of $100m through Leerink Partners as sales agent.
Oculis Holding, a late clinical-stage biopharmaceutical company focused on ophthalmic and neuro‑ophthalmic diseases, reports continued pre‑revenue investment in its pipeline, including OCS‑01 for diabetic macular edema, Licaminlimab for dry eye disease and Privosegtor for optic neuritis and related conditions.
For the year ended December 31, 2025, Oculis recorded a net loss of CHF 99.0 million, compared with CHF 85.8 million in 2024, bringing accumulated losses to CHF 384.5 million. The company held CHF 213.0 million in cash, cash equivalents and short‑term financial assets, which it believes will fund operations for at least the next twelve months. As of December 31, 2025, it had 57,984,438 ordinary shares, 2,104,906 warrants to purchase ordinary shares and 60 employees.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.